Simulations Plus is a developer of modeling and simulation software for drug discovery and development, and machine-learning-based technology. Co. also provides consulting services. Co. provides several software products for pharmaceutical research and development including: simulation programs that provide time-dependent results based on solving sets of differential equations: GastroPlus®; DDDPlus; MembranePlus; DILIsym®; and NAFLDsym; programs that are based on predicting and analyzing static properties of chemicals: ADMET Predictor®; MedChem Designer; and MedChem Studio; PKPlus; KIWI ; and the Monolix Suite of products, which is a modeling and simulation solution. The SLP stock yearly return is shown above.
The yearly return on the SLP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SLP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|